Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/177140
Title: | Differential response to intravitreal dexamethasone implant in naïve and previously treated diabetic macular edema eyes |
Author: | Zarranz Ventura, Javier Romero Núñez, Bárbara Bernal Morales, Carolina Velázquez Villoria, Daniel Sala Puigdollers, Anna Figueras Roca, Marc Copete, Sergio Distefano, Laura Boixadera, Anna García Arumí, José Adán Civera, Alfredo Hospital Clínic-Hospital Vall de Hebron Intravitre |
Keywords: | Edema Pròtesis internes Edema Stents (Surgery) |
Issue Date: | 11-Nov-2020 |
Publisher: | BioMed Central |
Abstract: | Background: To identify different response patterns to intravitreal dexamethasone implants (IDI) in naïve and previously treated (PT) diabetic macular edema (DME) eyes in a real-life setting. Methods: 342 IDI injections (203 DME eyes) were included. Number of IDI injections, percentage (%) of eyes with 1, 2, 3 and ≥ 4 injections, time to reinjections, visual acuity (VA), intraocular pressure (IOP) and central retinal thickness (CRT) were evaluated for naïve and PT DME eyes over 24 months. Results: Mean number of injections was significantly lower in naïve vs PT DME eyes (1.40 ± 0.9 vs 1.82 ± 0.9, p < 0.001). The percentage of eyes receiving 1 injection was significantly higher in naïve vs PT DME eyes (76.1 vs 47.7), (p < 0.001). However, it was significantly lower for 2 (16.4 vs 29.4), or 3 injections (1.4 vs 17.6) (both p < 0.001), with no differences in eyes receiving ≥4 injections (5.9 vs 5.1 respectively, p = 0.80). Mean time to reinjection was not significantly different between both groups for the second, third and fourth injection (9.6 ± 4.0 vs 10.0 ± 5.5, p = 0.75, 13.2 ± 4.0 vs 16.0 ± 3.5, p = 0.21 and 21.7 ± 3.8 vs 19.7 ± 5.8, p = 0.55). VA scores were consistently better in naïve vs PT DME eyes at all studied timepoints, with no significant differences in CRT reduction or adverse effect rates. Conclusion: Naïve DME eyes received lower number of IDI injections and showed better VA levels than PT DME eyes for 24 months in a real-world setting. This data supports the IDI use in early DME stages and provide further evidence of better IDI response when used as first-line therapy. |
Note: | Reproducció del document publicat a: https://doi.org/10.1186/s12886-020-01716-2 |
It is part of: | BMC Ophthalmology, 2020, vol. 20, num. 1, p. 443 |
URI: | https://hdl.handle.net/2445/177140 |
Related resource: | https://doi.org/10.1186/s12886-020-01716-2 |
ISSN: | 1471-2415 |
Appears in Collections: | Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques) Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
710224.pdf | 990.13 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License